Neurostimulation Device for Alzheimers Granted FDA …
WEBJan 25, 2021 · Non-invasive Neurostimulation Device Wins FDA’s Breakthrough Status. by Patricia Inacio, PhD January 25, 2021. Cognito Therapeutic ’s neurostimulation device — a next-generation digital therapeutic designed to treat memory and cognition symptoms in Alzheimer’s disease — has been granted a breakthrough device designation by the U.S ...
Latest Data on Alzheimer's Drug Namenda Confirms Beneficial …
WEBby Alice Melão April 24, 2017. Results from four recent studies confirmed the beneficial clinical effects of Namenda (memantine), an FDA-approved Alzheimer’s therapy, to treat the disease’s behavioral and functional symptoms in people with moderate to severe disease. The studies, sponsored by Allergan, are being presented in poster format ...
September is World Alzheimer’s Month; Sept. 21 is Alzheimer’s Day
WEBSep 6, 2022 · Since 2009, ADI has released a World Alzheimer Report on World Alzheimer’s Day and will again on Sept. 21. The reports, which make recommendations for policy and practice, are sources of information on dementia. For this year, the report will provide a global view of post-diagnosis care models, impediments, and best practices through essays, case studies, and shared global experiences.
Phase 3 Alzheimer's Trials of Gantenerumab Likely to Decide...
WEBMar 20, 2018 · Learning from past efforts. Gantenerumab is a fully human antibody that binds to aggregated beta-amyloid, a protein that accumulates in neurons and is the main component of the senile plaques characteristic of Alzheimer’s. Its development started about a decade ago, and included a wide range of preclinical and clinical studies.Among them are Scarlet RoAD — first a Phase 2 study, and later ...
Alzheimer's News Today Home | Alzheimer's News Today
WEBFosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data. Fosgonimeton, an investigational medication from Athira Pharma, failed to significantly improve cognitive and daily functioning in adults with mild to moderate Alzheimer’s disease who took part in a Phase 2/3 clinical trial, despite being safe and well tolerated, top-line data show.
Biomarker test to diagnose Alzheimer's wins FDA breakthrough...
WEBMay 2, 2024 · The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease from other neurodegenerative disorders. The test, developed by Roche in collaboration with Eli Lilly, is …
Exelon (Rivastigmine) - Alzheimer's News Today
WEBExelon is part of a class of drugs called cholinesterase inhibitors. It acts to reversibly block the function of acetylcholinesterase. By inhibiting this enzyme, it prevents the breakdown of the neurotransmitter acetylcholine and increases its levels in the brain. This can provide a temporary relief for some of the symptoms of AD, by improving ...
Approved Treatments for Alzheimer's Disease
WEBAug 1, 2024 · Namenda (memantine) is an approved medicine for the treatment of moderate to severe Alzheimer’s disease. When nerve cells are damaged, it is believed that some start to release excess glutamate, leading to too much calcium entering cells. Namenda works to block glutamate, which is involved in learning and memory, from accessing NMDA receptors ...
Simufilam for Alzheimer's Improves Cognition, Behavior After 6 …
WEBFeb 15, 2021 · Simufilam, an investigational oral medication being developed by Cassava Sciences, improved cognition and behavior in people with Alzheimer’s disease after six months of dosing in a clinical trial, interim data show. “Today’s data once again suggests simufilam could be a transformative, novel therapeutic,” Nadav Friedmann, MD, PhD ...
Study: Electromagnetic Device Improves Cognition in Alzheimer's...
WEBSep 25, 2019 · Electromagnetic Device Improves Cognition in Alzheimer’s Patients, Small Study Finds. NeuroEM Therapeutics ‘s MemorEMTM — a head-worn device that uses electromagnetic waves — has shown promising results in a preliminary clinical trial of people with mild-to-moderate Alzheimer’s disease. Seven of eight participants demonstrated ...